Spruce Biosciences, Inc. (SPRB) Key Metrics
SPRB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $114.0M
- Enterprise value
- $53.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.8
- Price / book
- 1.7 10-yr median 1.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.30
SPRB key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSPRB valuation Price multiples at each fiscal year-end price.
SPRB returns How much profit the business earns on the capital it uses.
SPRB per-share figures Results divided by the shares outstanding at year-end.
SPRB financial health Debt, liquidity and how easily interest is covered.
SPRB efficiency & capital use Working capital cycle and where the cash goes.
SPRB valuation history
SPRB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SPRB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SPRB cash returned to shareholders
SPRB price vs earnings per share
SPRB key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $66.8M | — | — | $50.3M | $203.2M | $1.10B | — | — |
| Enterprise value | $18.6M | — | — | −$22.4M | $120.7M | $951.9M | — | — |
| Price / sales | — | — | — | 25.6 | — | — | — | — |
| Price / book | 1.6 | — | — | 0.7 | 1.8 | 7.4 | — | — |
| EV / sales | — | — | — | -11.4 | — | — | — | — |
| Earnings yield | −58.4% | — | — | −91.7% | −20.8% | −2.7% | — | — |
| Free cash flow yield | −49.9% | — | — | −82.8% | −17.7% | −2.5% | — | — |
| Dividend yield | — | — | — | — | 0.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | 0.1% | 0.2% | 0.0% | — | — |
| Share price at fiscal year-end | $87.11 | $31.50 | $219.75 | $82.31 | $334.50 | $1,823.25 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | — | — | $3.21 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$50.83 | — | — | −$75.49 | −$69.63 | −$48.84 | −$22.87 | — |
| Operating cash flow per share | −$43.47 | — | — | −$68.14 | −$59.07 | −$45.50 | −$21.80 | — |
| Free cash flow per share | −$43.47 | — | — | −$68.16 | −$59.22 | −$45.63 | −$21.80 | — |
| Cash per share | $63.80 | — | — | $129.27 | $146.48 | $259.85 | $6.78 | — |
| Book value per share | $55.46 | — | — | $111.96 | $183.36 | $247.08 | −$52.93 | — |
| Tangible book value per share | $55.46 | — | — | $111.96 | $183.36 | $247.08 | −$52.93 | — |
| Dividends per share | — | — | — | — | $0.70 | — | — | — |
| Capex per share | $0.00 | — | — | $0.01 | $0.15 | $0.12 | $0.01 | — |
| Debt per share | $0.96 | — | — | $10.32 | $10.75 | $10.55 | $7.68 | — |
| Shares outstanding | 767K | — | — | 612K | 607K | 605K | 579K | — |
| Change in shares outstanding | — | — | — | +0.7% | +0.4% | +4.5% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −109.2% | −100.7% | −66.1% | −51.4% | −32.4% | −49.7% | — | — |
| Return on invested capital (ROIC) | — | — | — | — | −240.9% | — | — | — |
| Return on assets (ROA) | −79.3% | −71.1% | −50.5% | −43.5% | −29.2% | −35.3% | −279.6% | −206.5% |
| Return on tangible assets | −73.5% | −117.3% | −46.1% | −53.9% | −33.4% | −18.1% | −282.1% | −206.5% |
| Free cash flow margin | — | — | −329.9% | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $736,000 | $2.8M | $4.6M | $6.3M | $6.5M | $6.4M | $4.4M | — |
| Cash & short-term investments | $48.9M | $38.8M | $96.3M | $79.1M | $89.0M | $157.2M | $3.9M | $4.1M |
| Net debt | −$48.2M | −$36.0M | −$91.7M | −$72.8M | −$82.4M | −$150.8M | $521,000 | −$4.1M |
| Debt / equity | 0.02 | 0.10 | 0.06 | 0.09 | 0.06 | 0.04 | — | — |
| Debt / assets | 0.01 | 0.06 | 0.04 | 0.07 | 0.05 | 0.04 | 0.95 | — |
| Current ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 | 1.76 |
| Quick ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 | 1.76 |
| Interest coverage | -405.7 | -182.9 | -107.6 | -112.6 | -121.9 | -91.1 | -201.6 | — |
| Working capital | $42.0M | $29.0M | $77.7M | $71.2M | $83.0M | $150.6M | $349,000 | $2.1M |
| Invested capital | −$5.7M | −$7.2M | −$15.2M | −$4.3M | $28.9M | −$1.3M | −$30.1M | −$21.9M |
| Tangible asset value | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M | $149.4M | −$30.6M | −$17.8M |
| Net current asset value | $41.6M | $27.8M | $74.7M | $66.4M | $76.8M | $146.9M | −$30.7M | −$17.8M |
| Graham net-net per share | $50.09 | — | — | $101.22 | $121.59 | $237.60 | −$54.25 | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | $169,000 | — | $423,000 | — | — | — |
| Share buybacks (net) | $0 | $0 | $311,000 | $40,000 | $0 | $0 | — | — |
| Capex / revenue | — | 0.0% | 0.1% | 0.4% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.10 | 0.11 | 1.37 | 2.06 | 0.33 | 4.00 |
| Stock-based compensation / revenue | — | 108.9% | 45.8% | 184.9% | — | — | — | — |
| R&D / revenue | — | 945.2% | 490.0% | 1,792.2% | — | — | — | — |
| SG&A / revenue | — | 298.2% | 126.1% | 615.3% | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 19,449.3 | — | 17.6 | 1,807.6 | 3,090.0 | 9,851.4 | 63,540.4 | 839,500.0 |
| Payables turnover | 0.02 | 0.00 | 20.78 | 0.20 | 0.12 | 0.04 | 0.01 | 0.00 |
| Asset turnover | 0.00 | 0.07 | 0.11 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.1M | $2.3M | $2.4M | $2.1M | $3.2M | $2.8M | $2.1M | $2.3M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SPRB's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SPRB valuation and financial ratios
Spruce Biosciences earned a return on equity of −109.2% in fiscal 2025. It ended the year with $0.7 million of debt and $48.9 million in cash and short-term investments, a net cash position of $48.2 million.
See the SPRB income statement, the SPRB chart for price history, or the SPRB stock overview for the latest quote and news.
SPRB key metrics FAQ
What is Spruce Biosciences's return on equity?
Spruce Biosciences's return on equity (ROE) was −109.2% in fiscal 2025: net income of -$39.0 million on average shareholders' equity of $35.7 million.
How much debt does Spruce Biosciences have?
Spruce Biosciences had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Spruce Biosciences's free cash flow yield?
Spruce Biosciences generated -$33.3 million of free cash flow in fiscal 2025, a free cash flow yield of −49.9% on its market value at year-end ($66.8 million).
What is Spruce Biosciences's current ratio?
Spruce Biosciences's current ratio was 5.17 at the end of fiscal 2025: current assets were 5.17 times current liabilities.